Microtubule-associated Protein Tau (MAPT)

Microtubule-associated Protein Tau (MAPT) glycopeptides, which are glycosylated fragments of Tau, are utilized to explore potential therapeutic strategies, including targeted treatments and vaccines aimed at altering Tau function or preventing its abnormal aggregation. The deposition of microtubule-associated protein Tau (MAPT) is a defining feature of tauopathies, a group of neurodegenerative diseases. In conditions such as Alzheimer’s disease (AD), Tau undergoes significant remodeling, with post-translational modifications throughout the protein’s sequence linked to clinical symptoms. Systematic analysis of these modifications can offer vital insights into their roles in both healthy and diseased states.